{"id":"test","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108771","moleculeType":"Unknown"},"_dailymed":{"setId":"e2e6ce46-6729-4a63-90db-27e933379f45","title":"NATURAL TESTOSTERONE (AVENA SATIVA. EPIMEDIUM, LYCOPODIUM CLAVATUM, DAMIANA, TESTOSTERONE, AGNUS CASTUS) SPRAY [BIOACTIVE NUTRITIONAL, INC.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is used to treat various conditions by","oneSentence":"Test is a medication that works by","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:11:51.814Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various conditions"}]},"trialDetails":[{"nctId":"NCT06806592","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-09-13","conditions":"Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases","enrollment":400},{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":"Inflammation, Smoking Cessation, Diet Modification","enrollment":2000},{"nctId":"NCT04439201","phase":"PHASE2","title":"Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-31","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT02466971","phase":"PHASE3","title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-10","conditions":"Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma","enrollment":450},{"nctId":"NCT04491942","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-25","conditions":"Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma","enrollment":74},{"nctId":"NCT07496541","phase":"","title":"Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-17","conditions":"Primary Monosymptomatic Nocturnal Enuresis, Copeptin","enrollment":180},{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT07498556","phase":"NA","title":"Immediate Restoration of a New Implant With High Primary Stability","status":"NOT_YET_RECRUITING","sponsor":"Universidade do Porto","startDate":"2026-03-01","conditions":"Dental Implants, Immediate Dental Implant Loading","enrollment":50},{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":19},{"nctId":"NCT07156227","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-22","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT05053971","phase":"PHASE1, PHASE2","title":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma","enrollment":49},{"nctId":"NCT06985056","phase":"NA","title":"Reducing Symptom Burden Through Physical Exercise in Melanoma Patients","status":"RECRUITING","sponsor":"Universität Duisburg-Essen","startDate":"2025-08-18","conditions":"Malignant Melanoma","enrollment":104},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT07498829","phase":"NA","title":"Population Based Germline Testing for Early Detection and Prevention of Cancer","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2025-12-18","conditions":"Breast Cancer Risk, Ovarian Cancer Risk, Cancer Gene Mutation","enrollment":6000},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT04387656","phase":"","title":"NCI COVID-19 in Cancer Patients, NCCAPS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-05","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":1877},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT07061951","phase":"PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-09-08","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT03559283","phase":"NA","title":"fNIRS in the Evaluation of Cognitive-motor Interference in Post-stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2018-11-26","conditions":"D020521","enrollment":11},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT04166409","phase":"PHASE3","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-31","conditions":"Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma","enrollment":170},{"nctId":"NCT07497971","phase":"NA","title":"Utilizing Electronic Modules to Educate on Sexual Health Practices During Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Loyola University","startDate":"2026-03","conditions":"Sexual Health Education During Pregnancy, Communication About Sexual Health in Prenatal Care, Sexual Function and Intimacy in Pregnancy","enrollment":100},{"nctId":"NCT07253532","phase":"NA","title":"Vibrotactile Balance Belt Effect on Improving Gait","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03-20","conditions":"Vestibular Hypofunction, Ataxia - Other, Gait Impairment","enrollment":90},{"nctId":"NCT05842122","phase":"NA","title":"Pharmacy-based PrEP Delivery in Kenya","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-06-20","conditions":"Hiv","enrollment":5808},{"nctId":"NCT04439357","phase":"PHASE2","title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-25","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":4},{"nctId":"NCT01212003","phase":"","title":"Training Protocol on the Natural History of Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-30","conditions":"Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis","enrollment":150},{"nctId":"NCT04967677","phase":"","title":"Establishing of the Inter-rater Reliability and Variability of Selected Standardized Tests Performed in Czech Language","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2021-05-31","conditions":"Motor Activity","enrollment":30},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT05064293","phase":"NA","title":"Assisted Identification and Navigation of Early Mental Health Symptoms in Children","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-09-07","conditions":"Adolescent Behavior, Mental Health Issue","enrollment":358},{"nctId":"NCT04052555","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-24","conditions":"Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma","enrollment":42},{"nctId":"NCT07395258","phase":"PHASE1","title":"A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-03-30","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT04943224","phase":"PHASE2","title":"Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":"Histiocytosis","enrollment":12},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT06980038","phase":"PHASE2","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-21","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT03854474","phase":"PHASE1, PHASE2","title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-18","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT06400238","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-15","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT07495059","phase":"NA","title":"Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-03-01","conditions":"HIV (Human Immunodeficiency Virus), Continuum of Care, Stigma","enrollment":80},{"nctId":"NCT07147231","phase":"PHASE1, PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461) in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":86},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT07030166","phase":"","title":"A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients","status":"RECRUITING","sponsor":"Lanyue Zhu","startDate":"2025-07-01","conditions":"Kidney Injury, Acute","enrollment":10000},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT07495007","phase":"PHASE1","title":"An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection","status":"COMPLETED","sponsor":"Zi Diligence Biocenter","startDate":"2025-11-10","conditions":"Bioequivalance, Post-menopause","enrollment":26},{"nctId":"NCT00109174","phase":"NA","title":"MRS Measurement of Glutamate and GABA Metabolism in Brain","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2006-09-06","conditions":"Normal Physiology","enrollment":200},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT07313540","phase":"NA","title":"Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-10","conditions":"Aging, Dementia, Cognitive Decline","enrollment":40},{"nctId":"NCT03191149","phase":"PHASE2","title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-25","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7","enrollment":46},{"nctId":"NCT02728635","phase":"NA","title":"Epigenetic Regulation of Human Adipose Tissue Distribution","status":"ACTIVE_NOT_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2016-07","conditions":"Obesity","enrollment":27},{"nctId":"NCT06949969","phase":"NA","title":"Alesis OSA-1 Obstructive Sleep Apnea Treatment","status":"COMPLETED","sponsor":"Photonica USA, LLC","startDate":"2025-05-01","conditions":"Obstructive Sleep Apnea","enrollment":35},{"nctId":"NCT06979960","phase":"NA","title":"The Effect of Face-to-Face and Online Training on Cancer Screening on Women's Knowledge, Attıtude and Shyness","status":"COMPLETED","sponsor":"Inonu University","startDate":"2024-09-01","conditions":"Being Literate, Not Having Any Cognitive, Visual or Orthopedic Disabilities, Being Between the Ages of 50-65","enrollment":68},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT01989585","phase":"PHASE1, PHASE2","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm","enrollment":75},{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":"Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm","enrollment":298},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT05077904","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-12-07","conditions":"Stereotypical Prolonged Seizures","enrollment":350},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":"Asthma","enrollment":2700},{"nctId":"NCT07498153","phase":"NA","title":"Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-09-30","conditions":"Syphilis, HIV Infections","enrollment":149},{"nctId":"NCT07496606","phase":"NA","title":"Effect of an Audio Instructional Program Regarding Puberty on Self-Concept and Healthy Behaviors of Teenage Girls With Visual Impairment","status":"COMPLETED","sponsor":"Al-Quds University","startDate":"2024-10-01","conditions":"Healthy, Teenagers, Girls","enrollment":46},{"nctId":"NCT05223036","phase":"PHASE2","title":"Testing Obeticholic Acid for Familial Adenomatous Polyposis","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-19","conditions":"Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma","enrollment":80},{"nctId":"NCT05499130","phase":"PHASE2","title":"A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2022-09-30","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":290},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT06747221","phase":"NA","title":"Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya","status":"NOT_YET_RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2026-06-01","conditions":"HIV","enrollment":184},{"nctId":"NCT06308822","phase":"PHASE2","title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT01267955","phase":"PHASE2","title":"Vismodegib in Treating Patients With Advanced Chondrosarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-21","conditions":"Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma","enrollment":45},{"nctId":"NCT01841723","phase":"PHASE2","title":"Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-04-30","conditions":"Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia","enrollment":44},{"nctId":"NCT06695780","phase":"","title":"Food Typologies and Multidimensional Phenotyping of Elderly in Auvergne-Rhône-Alpes (Part'AGE)","status":"RECRUITING","sponsor":"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement","startDate":"2025-02-03","conditions":"Nutritional Assessment, Physical Activity, Health","enrollment":1000},{"nctId":"NCT02893917","phase":"PHASE2","title":"Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-11","conditions":"Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","enrollment":90},{"nctId":"NCT05327010","phase":"PHASE2","title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-14","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":88},{"nctId":"NCT06888323","phase":"PHASE1","title":"Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-27","conditions":"Refractory Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT05188573","phase":"NA","title":"EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients","status":"WITHDRAWN","sponsor":"ClearNote Health","startDate":"2022-06-01","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT03854318","phase":"","title":"Longitudinal Studies of Patient With FPDMM","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-03-28","conditions":"Inherited Hematological Diseases, Rare Diseases, FPDMM","enrollment":1000},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT06995898","phase":"NA","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-16","conditions":"Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma","enrollment":24000},{"nctId":"NCT06941831","phase":"NA","title":"Rwanda Digital Dashboard Hybrid Type 3 Implementation Study","status":"RECRUITING","sponsor":"Boston College","startDate":"2025-01-30","conditions":"IPV, Mental Health, Discipline Practices","enrollment":1810},{"nctId":"NCT06351371","phase":"PHASE2","title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-03","conditions":"Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT07498972","phase":"NA","title":"Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanxi Province Cancer Hospital","startDate":"2023-01-01","conditions":"Advanced Lung Cancer, Cancer-related Fatigue","enrollment":100},{"nctId":"NCT07498712","phase":"NA","title":"Effect of L. Reuteri LM1063 on Sleep Health Improvement","status":"RECRUITING","sponsor":"Lactomason Co., Ltd.","startDate":"2025-07-14","conditions":"Sleep Quality, Sleep Wake Disorders","enrollment":80},{"nctId":"NCT05124041","phase":"NA","title":"Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-11-15","conditions":"Acute on Chronic Liver Failure, Variceal Hemorrhage, Cirrhosis, Liver","enrollment":262},{"nctId":"NCT06917911","phase":"PHASE2","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-18","conditions":"Core Binding Factor Acute Myeloid Leukemia","enrollment":162},{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT06545214","phase":"NA","title":"Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-11-04","conditions":"Epilepsy","enrollment":60},{"nctId":"NCT07174648","phase":"","title":"Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2026-05-01","conditions":"Plague, Bubonic; Plague, Skin, Plague, Pneumonic","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":33,"reaction":"DIZZINESS"},{"count":33,"reaction":"DYSPNOEA"},{"count":28,"reaction":"FATIGUE"},{"count":28,"reaction":"HEADACHE"},{"count":27,"reaction":"DIARRHOEA"},{"count":27,"reaction":"DRUG INEFFECTIVE"},{"count":27,"reaction":"NAUSEA"},{"count":25,"reaction":"ASTHENIA"},{"count":24,"reaction":"PRURITUS"},{"count":24,"reaction":"RASH"}],"_approvalHistory":[{"date":"20101005","type":"ORIG","sponsor":"PHARMAXIS EUROPE","applicationNumber":"NDA022368"},{"date":"20210813","type":"SUPPL","sponsor":"PHARMAXIS EUROPE","applicationNumber":"NDA022368"}],"publicationCount":2104955,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals","T.R.U.E. TEST","Placebo","HLIM+SA160021 Placebo+SA160022 Placebo","CMT"],"phase":"marketed","status":"active","brandName":"Test","genericName":"Test","companyName":"Respirent Pharmaceuticals Co Ltd.","companyId":"respirent-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Test is a medication that works by Used for Various conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":10,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}